Abstract
BackgroundRecent studies have shown that CD90 has an important role in cancer development. Moreover, CD90 is reportedly associated with cancer progression, metastasis, and poor prognosis. Thus, we performed this meta-analysis to investigate the prognostic and clinicopathological value of CD90 expression in patients with cancer.MethodsEligible studies were collected by searching PubMed, Embase, and the Cochrane library. The pooled results were analyzed to reveal the association between CD90 expression and survival as well as the clinicopathological characteristics of cancer patients.ResultsCD90 overexpression was associated with poor survival in cancer patients [for overall survival, hazard ratio (HR): 2.56, 95% confidence interval (CI): 1.42–4.62, P=0.002; for disease-free survival, HR: 1.88, 95% CI: 1.08–3.27, P=0.025] and was also significantly correlated with a larger tumor size [odds ratio (OR): 1.97, 95% CI: 1.01–3.85, P=0.048), higher tumor grade (OR: 2.72, 95% CI: 1.33–5.54, P=0.006), lymph node metastasis (OR: 3.66, 95% CI: 1.14–11.78, P=0.029), and higher tumor-node-metastasis stage (OR: 4.79, 95% CI: 2.28–10.04, P<0.001).ConclusionsCD90 overexpression could predict poor prognosis and may hence be a potential prognostic biomarker for cancer patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
